IPO
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, announces the results of its rights issue for a limited amount of € 521 K.
Turku, Finland, July 19th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.
Assertio Therapeutics, Inc. announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets.
Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
RA Capital Management, LLC announced the first and final closing of its inaugural venture fund, RA Capital Nexus Fund, L.P., at just over $300 million, boosting RA Capital’s private deal capacity to nearly $1 billion and total assets under management to approximately $2.5 billion.
vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury, announced the successful completion of a €9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments.
PRESS RELEASES